Myriad Genetics (MYGN) Short-term Investments (2010 - 2024)

Myriad Genetics (MYGN) has 15 years of Short-term Investments data on file, last reported at $4.9 million in Q2 2024.

• Short-term Investments for Q2 2024 came in at $4.9 million, down 73.94% year-over-year; the trailing twelve-month figure through Jun 2024 was $4.9 million (down 73.94% YoY), and the FY2023 annual result was $8.8 million, down 84.83% from the prior year.
• Short-term Investments retreated to $4.9 million in Q2 2024 per MYGN's latest filing, from $7.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $103.2 million in Q1 2022 and troughed at $4.9 million in Q2 2024.
• A 5-year average of $46.4 million and a median of $44.0 million in 2020 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments surged 279.41% in 2022, then plunged 87.52% in 2023.
• A 5-year view of Short-term Investments shows it stood at $33.7 million in 2020, then soared by 141.54% to $81.4 million in 2021, then decreased by 28.75% to $58.0 million in 2022, then sank by 84.83% to $8.8 million in 2023, then plunged by 44.32% to $4.9 million in 2024.
• Business Quant data shows MYGN's Short-term Investments at $4.9 million in Q2 2024, $7.4 million in Q1 2024, and $8.8 million in Q4 2023.